Animal Model Market By Animal Type (Rodents, Non-Rodents), By Model Type (Xenograft Models, Knockout & Transgenic Models, Syngeneic Models, Hybrid Models), By Application (Cancer Research, Neurological Diseases, Infectious Diseases, Genetic Disorders, Immunological Studies, Drug Discovery & Development), By End User (Pharmaceutical & Biotech Companies, Academic & Research Institutions, Contract Research Organizations (CROs)), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Animal Model Market was valued at USD 2.4 billion in 2024-e and will surpass USD 4.2 billion by 2030; growing at a CAGR of 9.8% during 2025 - 2030.

The animal model market is expanding rapidly, driven by the increasing demand for preclinical research in drug discovery, disease modeling, and biomedical studies. Animal models play a crucial role in understanding disease mechanisms, evaluating therapeutic interventions, and ensuring the safety and efficacy of new drugs before human trials. With the rise in chronic diseases, neurological disorders, and infectious diseases, researchers and pharmaceutical companies are relying heavily on animal models to accelerate medical advancements.

Technological advancements, such as genetically engineered models and humanized animal models, have further strengthened the market. The growing emphasis on precision medicine and personalized therapies has increased the demand for more accurate and disease-relevant models. Additionally, regulatory agencies continue to emphasize the importance of preclinical validation, driving consistent market growth. However, ethical concerns and the push for alternative testing methods remain key challenges shaping the industry's future.

Rodents are Largest Animal Type Owing to High Reproducibility and Genetic Similarity

Rodents, particularly mice and rats, dominate the animal model market due to their genetic similarity to humans, short reproductive cycles, and ease of genetic manipulation. These factors make rodents ideal for studying a wide range of diseases, including cancer, genetic disorders, and neurodegenerative diseases. Their widespread availability, cost-effectiveness, and established usage in regulatory preclinical testing further contribute to their leadership in the market.

The advancement of transgenic and knockout rodent models has significantly enhanced research capabilities, allowing scientists to mimic human diseases more precisely. Rodents are also heavily utilized in toxicology studies, drug metabolism research, and vaccine development, further strengthening their market presence. As biomedical research continues to evolve, rodents will remain the preferred choice for preclinical studies due to their reliability and adaptability in diverse research applications.

Xenograft Models are Fastest Growing Model Type Owing to Rising Cancer Research Applications

Xenograft models are witnessing the fastest growth in the animal model market, primarily driven by their increasing use in oncology research. These models, which involve transplanting human tumor cells into immunodeficient animals, provide a highly relevant platform for studying tumor growth, drug efficacy, and personalized cancer therapies. The rise in cancer prevalence and the urgent need for more effective treatments have accelerated the adoption of xenograft models in preclinical research.

Advancements in patient-derived xenograft (PDX) models have further fueled market growth, allowing for a more accurate representation of human tumor biology. Pharmaceutical and biotech companies are increasingly relying on these models to optimize drug development pipelines, leading to faster clinical translation of new oncology drugs. With ongoing innovations in immuno-oncology and targeted therapies, the demand for xenograft models is expected to surge in the coming years.

Cancer Research is Largest Application Owing to High Demand for Preclinical Oncology Studies

Cancer research remains the largest application segment in the animal model market, driven by the global burden of cancer and the continuous search for effective treatments. Animal models are indispensable for understanding tumor biology, testing novel drug candidates, and evaluating immunotherapies. The development of genetically engineered models, such as transgenic mice with specific oncogenes, has significantly advanced oncology research by providing more precise disease modeling.

Pharmaceutical and biotech companies heavily invest in preclinical oncology studies using animal models to identify promising drug candidates before human trials. The rise of precision medicine has also increased the demand for patient-derived xenograft (PDX) models, which replicate human tumor heterogeneity more accurately. With cancer remaining a major focus area for drug development, the use of animal models in oncology research is expected to remain dominant.

Pharmaceutical & Biotech Companies are Largest End User Owing to Extensive Drug Development Activities

Pharmaceutical and biotech companies represent the largest end-user segment in the animal model market due to their extensive use of preclinical testing for drug development. Before any new drug advances to clinical trials, it must undergo rigorous animal testing to assess its safety, efficacy, and potential side effects. Given the high failure rate of drugs in human trials, robust preclinical validation using animal models is essential for minimizing risks and optimizing therapeutic outcomes.

The increasing focus on biologics, gene therapies, and immunotherapies has further driven the demand for sophisticated animal models among pharma and biotech firms. These companies are investing in advanced models, such as genetically modified mice and humanized animals, to enhance the predictive accuracy of preclinical studies. As drug development pipelines expand, the reliance on animal models will continue to grow, making pharmaceutical and biotech companies the dominant end users in this market.

North America is Largest Region Owing to Strong Research Infrastructure and High R&D Investments

North America holds the largest share of the animal model market, driven by its well-established biomedical research infrastructure, significant R&D investments, and presence of leading pharmaceutical and biotech companies. The region's regulatory framework supports extensive preclinical research, ensuring compliance with ethical standards while promoting advancements in animal modeling techniques. The increasing adoption of genetically engineered models and humanized animals has further strengthened market growth.

The high prevalence of chronic diseases, particularly cancer and neurodegenerative disorders, has fueled the demand for innovative preclinical research solutions in North America. The region's strong academic and research institutions, coupled with collaborations between industry and government agencies, continue to accelerate the development of next-generation therapies. As precision medicine and targeted drug development gain traction, North America is expected to maintain its leading position in the global animal model market.

Leading Companies and Competitive Landscape

The animal model market is highly competitive, with key players such as Charles River Laboratories, Taconic Biosciences, The Jackson Laboratory, Envigo, and GenOway leading the industry. These companies focus on developing genetically engineered models, expanding their animal model portfolios, and enhancing research capabilities to meet the evolving needs of pharmaceutical and biotech firms. Strategic partnerships, acquisitions, and collaborations with research institutions play a crucial role in shaping market competition.

As ethical concerns and regulatory scrutiny increase, companies are also investing in alternative methods, such as organ-on-a-chip technology and computational modeling, to complement animal studies. However, the demand for reliable and disease-specific animal models remains strong, ensuring continued market growth. The competitive landscape will likely be defined by innovation in genetic engineering, strategic alliances, and advancements in preclinical research methodologies.

List of Leading Companies:

• Charles River Laboratories International, Inc.
• The Jackson Laboratory
• Taconic Biosciences, Inc.
• Envigo
• Janvier Labs
• GenOway
• Crown Bioscience, Inc.
• Cyagen Biosciences
• Laboratory Corporation of America Holdings (Labcorp)
• Horizon Discovery Group plc
• Inotiv Inc.
• Beijing Vital River Laboratory Animal Technology Co., Ltd.
• Biomere
• Ozgene Pty Ltd.
• TransViragen, Inc.

Recent Developments:

• In January 2025, Charles River Laboratories expanded its humanized mouse model portfolio for immuno-oncology research.
• In December 2024, The Jackson Laboratory launched new genetically modified mice for Alzheimer’s disease studies.
• In November 2024, Taconic Biosciences partnered with a biotech firm to develop CRISPR-edited rodent models.
• In October 2024, Envigo announced an investment in expanded breeding facilities to meet rising global demand.
• In September 2024, Crown Bioscience introduced a novel xenograft model platform for personalized cancer research.

Report Scope: